Raltitrexed (Tomudex):: an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity

被引：62
|
作者：
Köhne, CH
Thuss-Patience, P
Friedrich, M
Daniel, PT
Kretzschmar, A
Benter, T
Bauer, B
Dietz, R
Dörken, B
机构：
[1] Humboldt Univ, Med Fak Charite, Virchow Klinikum,Robert Rossle Klin, Dept Haematol Oncol & Tumor Immunol, D-13125 Berlin, Germany
[2] Humboldt Univ, Med Fak Charite, Virchow Klinikum,Franz Volhard Klin, Dept Clin & Mol Cardiol, D-13125 Berlin, Germany
来源：
BRITISH JOURNAL OF CANCER | 1998年 / 77卷 / 06期
关键词：
5-fluorouracil; cardiotoxicity; raltitrexed; colorectal neoplasms;
D O I：
10.1038/bjc.1998.160
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Two patients with proven 5-fluorouracil (5-FU)-associated cardiotoxicity were treated with the specific thymidylate synthase inhibitor raltitrexed safely, without evidence of cardiotoxicity. Raltitrexed might be an alternative for patients with advanced colorectal cancer and 5-FU-associated cardiotoxicity. 5-FU cardiotoxicity is not due to the antineoplastic mechanisms via thymidilate synthase.
引用
收藏
页码：973 / 977
页数：5
相关论文
共 50 条
  • [41] CLINICAL CARDIOTOXICITY OF 5-FLUOROURACIL
    KEEFE, DL
    ROISTACHER, N
    PIERRI, MK
    JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (11): : 1060 - 1070
  • [42] The spectrum of 5-fluorouracil cardiotoxicity
    Dalzell, Jonathan R.
    Samuel, Leslie M.
    ANTI-CANCER DRUGS, 2009, 20 (01) : 79 - 80
  • [43] 5-fluorouracil and cardiotoxicity: a review
    Sara, Jaskanwal D.
    Kaur, Jasvinder
    Khodadadi, Ryan
    Rehman, Muneeb
    Lobo, Ronstan
    Chakrabarti, Sakti
    Herrmann, Joerg
    Lerman, Amir
    Grothey, Axel
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [44] Raltitrexed (Tomudex™) in combination treatment for colorectal cancer:: New perspectives
    Van Cutsem, E
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S1 - S2
  • [45] 'Tomudex' (raltitrexed) has a manageable toxicity profile in elderly patients with metastatic colorectal cancer
    Facchini, T
    Genet, D
    Berdah, JF
    Nouyrigat, P
    Dutin, JP
    Laplaige, P
    Smith, M
    Haguenauer, C
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S80 - S80
  • [46] Costs Associated With Complications Are Lower With Capecitabine Than With 5-Fluorouracil in Patients With Colorectal Cancer
    Chu, Edward
    Schulman, Kathy L.
    Zelt, Susan
    Song, Xue
    CANCER, 2009, 115 (07) : 1412 - 1423
  • [47] MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil
    Fahima Danesh Pouya
    Maria Gazouli
    Yousef Rasmi
    Dimitra Ioanna Lampropoulou
    Mohadeseh Nemati
    Molecular Biology Reports, 2022, 49 : 5165 - 5178
  • [48] MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil
    Pouya, Fahima Danesh
    Gazouli, Maria
    Rasmi, Yousef
    Lampropoulou, Dimitra Ioanna
    Nemati, Mohadeseh
    MOLECULAR BIOLOGY REPORTS, 2022, 49 (06) : 5165 - 5178
  • [49] Therapeutic drug monitoring of 5-fluorouracil (5-FU) in the treatment of patients with colorectal cancer (CRC)
    Goel, Gaurav
    Sehgal, Rajesh
    Meisner, Dennis James
    Sun, Min
    Pasricha, Gurleen
    Chu, Edward
    Lee, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [50] Oral status in patients receiving 5-fluorouracil for colorectal cancer
    Djuric, M.
    Cakic, S.
    Hadzi-Mihailovic, M.
    Petrovic, D.
    Jankovic, L.
    JOURNAL OF BUON, 2010, 15 (03): : 475 - 479
12345